Retatrutide is a new pharmaceutical in the fight against obesity. This groundbreaking drug, belonging to a dual GLP-1 and GIP receptor agonist, exhibits promising results in clinical trials. By boosting these receptors, Retatrutide controls cravings, {promotesenergy expenditure, and ultimately contributes to significant weight loss. While research